Johannes Roth Selected Research

Systemic Lupus Erythematosus (Libman-Sacks Disease)

1/2016	CREM Alpha Enhances IL-21 Production in T Cells In Vivo and In Vitro.
9/2011	A novel intronic cAMP response element modulator (CREM) promoter is regulated by activator protein-1 (AP-1) and accounts for altered activation-induced CREM expression in T cells from patients with systemic lupus erythematosus.
10/2009	Phagocyte-specific S100A8/A9 protein levels during disease exacerbations and infections in systemic lupus erythematosus.
11/2005	The cyclic AMP response element modulator regulates transcription of the TCR zeta-chain.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Johannes Roth Research Topics

Disease

69	Inflammation (Inflammations) 12/2023 - 11/2002
26	Infections 03/2024 - 04/2004
23	Juvenile Arthritis (Juvenile Idiopathic Arthritis) 07/2023 - 09/2003
22	Arthritis (Polyarthritis) 01/2023 - 06/2003
17	Neoplasms (Cancer) 01/2023 - 08/2005
15	Sepsis (Septicemia) 02/2023 - 10/2005
6	Rheumatoid Arthritis 12/2019 - 06/2003
6	Rheumatic Diseases (Rheumatism) 01/2019 - 07/2007
5	Contact Dermatitis (Eczema, Contact) 12/2022 - 03/2007
5	Vasculitis (Vasculitides) 01/2022 - 09/2004
5	Osteoarthritis 09/2019 - 05/2012
5	Necrosis 01/2016 - 08/2005
4	Breast Neoplasms (Breast Cancer) 01/2023 - 11/2008
4	Pain (Aches) 01/2023 - 01/2014
4	Synovitis 01/2023 - 05/2005
4	Peritonitis 12/2022 - 12/2009
4	Granuloma 12/2022 - 06/2007
4	Pneumonia (Pneumonitis) 11/2022 - 05/2007
4	Osteoporosis 11/2021 - 08/2007
4	Autoimmune Diseases (Autoimmune Disease) 01/2021 - 09/2003
4	Experimental Arthritis 01/2018 - 11/2010
4	Systemic Lupus Erythematosus (Libman-Sacks Disease) 01/2016 - 11/2005
4	Shock 04/2015 - 09/2007
4	Hypersensitivity (Allergy) 08/2014 - 03/2007
4	Mucocutaneous Lymph Node Syndrome (Kawasaki Disease) 12/2007 - 04/2003
3	Inflammatory Bowel Diseases (Inflammatory Bowel Disease) 01/2023 - 01/2016
3	Lung Injury 01/2023 - 01/2013
3	Septic Shock (Toxic Shock Syndrome) 01/2021 - 12/2014
3	Neoplasm Metastasis (Metastasis) 12/2020 - 01/2017
3	Wounds and Injuries (Trauma) 01/2018 - 10/2012
3	Acute Lung Injury 01/2017 - 05/2007
3	Joint Diseases (Joint Disease) 10/2016 - 12/2005
3	Human Influenza (Influenza) 01/2014 - 10/2009
3	Cryopyrin-Associated Periodic Syndromes 12/2011 - 12/2008
2	Leukemia 10/2023 - 04/2015
2	Nephrotic Syndrome (Syndrome, Nephrotic) 10/2023 - 04/2015
2	Virus Diseases (Viral Diseases) 02/2023 - 11/2008
2	Familial Mediterranean Fever (Periodic Disease) 01/2023 - 04/2010
2	Crohn Disease (Crohn's Disease) 01/2023 - 03/2015
2	Urinary Tract Infections (Urinary Tract Infection) 01/2022 - 09/2013
2	Tonsillitis 09/2021 - 06/2021
2	Bacterial Infections (Bacterial Infection) 06/2021 - 01/2018
2	Diabetes Mellitus 01/2021 - 12/2015
2	Peritonsillar Abscess 01/2021 - 01/2017
2	Psoriatic Arthritis 01/2021 - 06/2003
2	Cystic Fibrosis (Mucoviscidosis) 01/2021 - 01/2020

Drug/Important Bio-Agent (IBA)

47	Proteins (Proteins, Gene)FDA Link 01/2023 - 06/2003
30	AlarminsIBA 01/2023 - 09/2009
28	Biomarkers (Surrogate Marker)IBA 01/2023 - 06/2004
19	CytokinesIBA 12/2022 - 10/2009
16	Toll-Like Receptor 4IBA 01/2023 - 09/2007
15	S100A12 ProteinIBA 12/2015 - 04/2003
13	Leukocyte L1 Antigen Complex (Calgranulin)IBA 01/2021 - 11/2002
13	S100 Proteins (S 100 Protein)IBA 12/2020 - 06/2003
11	LigandsIBA 01/2023 - 12/2007
9	GlucocorticoidsIBA 10/2023 - 01/2012
7	CalciumIBA 12/2022 - 06/2004
6	Methotrexate (Mexate)FDA LinkGeneric 09/2022 - 06/2003
6	AntigensIBA 01/2018 - 06/2003
6	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 09/2013 - 05/2005
5	Interleukin-6 (Interleukin 6)IBA 01/2021 - 10/2005
5	Interleukin-1 (Interleukin 1)IBA 01/2021 - 01/2010
5	EndotoxinsIBA 04/2015 - 09/2007
5	Receptor for Advanced Glycation End ProductsIBA 01/2015 - 04/2003
4	Messenger RNA (mRNA)IBA 12/2022 - 11/2005
4	Anti-Bacterial Agents (Antibiotics)IBA 01/2021 - 10/2010
4	InterleukinsIBA 01/2021 - 12/2011
4	C-Reactive ProteinIBA 01/2021 - 10/2005
4	Pattern Recognition ReceptorsIBA 01/2019 - 10/2005
4	ChemokinesIBA 04/2014 - 01/2013
4	Matrix Metalloproteinases (MMPs)IBA 08/2011 - 11/2003
3	Interleukin-1 Receptors (Interleukin 1 Receptor)IBA 07/2023 - 10/2016
3	Insulin (Novolin)FDA Link 12/2022 - 02/2017
3	Irritants (Vesicants)IBA 12/2022 - 01/2018
3	Peroxidase (Myeloperoxidase)IBA 01/2022 - 10/2010
3	Antigen-Antibody Complex (Immune Complex)IBA 01/2022 - 11/2003
3	tocilizumab (atlizumab)FDA Link 10/2021 - 04/2014
3	Interleukin-17 (Interleukin 17)IBA 01/2020 - 06/2010
3	AutoantibodiesIBA 01/2020 - 09/2005
3	Peptides (Polypeptides)IBA 01/2018 - 06/2014
3	Pathogen-Associated Molecular Pattern MoleculesIBA 01/2017 - 07/2007
3	Interleukin-8 (Interleukin 8)IBA 12/2015 - 10/2005
3	Calcium-Binding ProteinsIBA 01/2015 - 04/2003
3	EnzymesIBA 05/2014 - 12/2007
3	LipopolysaccharidesIBA 08/2013 - 10/2009
2	InflammasomesIBA 12/2023 - 07/2012
2	Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link 07/2023 - 12/2011
2	Imiquimod (Aldara)FDA LinkGeneric 01/2023 - 01/2020
2	PyrinIBA 01/2023 - 11/2015
2	LipidsIBA 12/2022 - 12/2020
2	SteroidsIBA 11/2021 - 04/2015
2	Interleukin-18 (Interleukin 18)IBA 06/2021 - 01/2020
2	Vitamin D FDA LinkGeneric 01/2021 - 01/2012
2	paquinimodIBA 01/2021 - 07/2015
2	Rheumatoid FactorIBA 01/2021 - 01/2016

Therapy/Procedure

26	Therapeutics 09/2023 - 08/2005
3	Critical Care (Surgical Intensive Care) 09/2023 - 01/2021
3	Biological Therapy 07/2023 - 09/2012
2	Operative Surgical Procedures 09/2021 - 01/2018
2	Tonsillectomy 09/2021 - 06/2021